Supplementary Figure S1 Step 1 (single) Step 2 (triple) 1x106/kg, single n = 3 Cohort 1 Cohort 3 1x106/kg, Triple n = 3 Cohort 4 3x106/kg, Triple n = 3 Cohort 2 1x107/kg, single n = 3 1x107/kg, Triple n = 4 Cohort 5 Cohort 6 3x107/kg, Triple n = 4 Supplementary Figure S1. Clinical treatment protocol. Step 1 includes single-dose infusion of 1×106 or 1×107 allogeneic NK cells/kg. When each single dose was determined to be safe, step 2, a triple infusion, was started. Arrows indicate the sequential order of administration procedure among cohorts. 2

Supplementary Figure S2 B CD16+CD56+ CD3+ CD14+ CD19+ 20 40 60 80 100 % of expression 92.93 ± 2.1% Viability 20 40 60 80 100 Viability (%) C D D0 D14 100 101 102 103 104 Fold expansion 3:1 1:1 0.3:1 20 40 60 80 100 E:T ratio % lysis 757.5 ± 223.2 Supplementary Figure S2. Characterization of ex vivo-expanded NK cells. (A) T cell-depleted PBMCs from healthy donors were expanded for 14 days in a GMP-compliant facility. The percentages of CD16+CD56+, CD3+, CD14+ and CD19+ cells were analyzed by flow cytometric analyses (n = 42). (B) The viability of expanded NK cells was evaluated by staining with propidium iodide (n = 16). (C) NK cell numbers were assessed before (D0) and after (D14) NK cell expansion and are expressed as fold expansion (n = 16). (D) Cytotoxicity of expanded NK cells against the K562 cell line was analyzed by flow cytometric cytotoxicity assay with the indicated E:T ratio in triplicate (n = 42). Each point represents mean ± SD. 1

Supplementary Figure S3 donor KIR A/A donor KIR A/B B Supplementary Figure S3. Analysis of donor KIR genotype and clinical outcome. Donors with KIR genotype A/A (n=7) or A/B (n=10) were reclassified by clinical outcome of recipients (A). Each number of patients with SD (open bar) or PD (solid bar) from donor KIR genotype A/A or KIR genotype A/B is presented (B). SD, stable disease; PD, progressive disease. 3

Supplementary Figure S4 Cohort 6-2 Sensitivity 1st 2nd 3rd therapy HGH Donor HLA-DRB1 B Cohort 6-4 Supplementary Figure S4. Kinetics of donor NK cells in the peripheral blood of recipients. Genomic DNA was extracted from serially-acquired PBMCs of the recipients. The persistence of donor NK cells in the peripheral blood of recipients was determined by allo-HLA-DRB1-specific PCR as described in the Materials and Methods. The sensitivity of nested PCR was analyzed by mixing decreasing amount of DNA from each donor with DNA of a recipient to give final concentrations of 10%, 1%, 0.1%, 0.01% and 0.001% (vol/vol). In Figure A and B, each gel picture shows result of three independent PCR reactions from serially obtained sera of cohort 6-2 (A) and 6-4 (B). The upper band for the HGH gene served as an internal positive control. Lower band indicates donor HLA-DRB1. Each assay was performed three times. 4

Supplementary Figure S5 FSC-A F S C - H 98.5 A 5.24 : CD14&CD19 91.4 CD3 CD56 9.76 4.13 75.2 10.9 CD4 CD8 51.3 0.4 32.2 16.1 NKG2D 99.1 0.286 97.7 NK CD8+ T CD4+ T B Supplementary Figure S5. NKG2D expression on NK and T cells in patients’ peripheral blood. The percentage of NKG2D+ NK cells, CD8 + T cell and CD4 + T cells was analyzed in lympho-gating of patients’ PBMCs by flow cytometry. Representative FACS dot plots and histograms are presented (B). Gating strategy and representative FACS dot plots are presented (A). 5